Metastatic Or Unresectable Melanoma clinical trials

Explore recruiting metastatic or unresectable melanoma clinical trials.

Recruiting metastatic or unresectable melanoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Or Unresectable Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open label, single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in checkpoint inhibitor treatment naïve adults with unresectable or metastatic melanoma

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma

Czechia, Germany, Belgium, Spain, Austria, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors

Spain, Italy, France, Belgium, Czechia, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab vs Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma

Romania, Finland, Austria, Italy, Germany, Belgium +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

Metastatic Or Unresectable Melanoma trials by city

Metastatic Or Unresectable Melanoma in Toronto Metastatic Or Unresectable Melanoma in Vancouver Metastatic Or Unresectable Melanoma in Montreal Metastatic Or Unresectable Melanoma in Calgary Metastatic Or Unresectable Melanoma in Edmonton Metastatic Or Unresectable Melanoma in Ottawa Metastatic Or Unresectable Melanoma in Winnipeg Metastatic Or Unresectable Melanoma in Quebec City Metastatic Or Unresectable Melanoma in Hamilton Metastatic Or Unresectable Melanoma in Kitchener Metastatic Or Unresectable Melanoma in London Metastatic Or Unresectable Melanoma in Halifax Metastatic Or Unresectable Melanoma in New York Metastatic Or Unresectable Melanoma in Los Angeles Metastatic Or Unresectable Melanoma in Chicago Metastatic Or Unresectable Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease